当前位置: X-MOL 学术Phytomedicine › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Geniposide ameliorates atherosclerosis by restoring lipophagy via suppressing PARP1/PI3K/AKT signaling pathway
Phytomedicine ( IF 6.7 ) Pub Date : 2024-04-10 , DOI: 10.1016/j.phymed.2024.155617
Jinhai Lin 1 , Xiaolong Wang 2 , Mingyang Gu 2 , Yuanyuan Chen 3 , Jiongbo Xu 2 , Nhi Van Chau 4 , Junlong Li 5 , Xiaodong Ji 6 , Qingmin Chu 5 , Lijin Qing 5 , Wei Wu 5
Affiliation  

Atherosclerosis (AS) is the leading cause of global death, which manifests as arterial lipid stack and plaque formation. Geniposide is an iridoid glycoside extract from Gardenia jasminoides J.Ellis that ameliorates AS by mediating autophagy. However, how Geniposide regulates autophagy and treats AS remains unclear. To evaluate the efficacy and mechanism of Geniposide in treating AS. , Geniposide reversed high-fat diet-induced hyperlipidemia, plaque progression, and inflammation. , Geniposide inhibited VSMC-derived foam cell formation by suppressing lipid stack, apoptosis, and the expressions of foam cell markers. Network pharmacological analysis and validation suggested that Geniposide treated AS by enhancing lipophagy via suppressing the PI3K/AKT signaling pathway. The benefits of Geniposide in alleviating AS were offset by Chloroquine and . Inhibiting PARP1 using Olaparib promoted lipophagy and alleviated AS progression, while PARP1 overexpression exacerbated foam cell formation and lipophagy blockage. The above effects of PARP1 were weakened by PI3K inhibitor LY294002. PARP1 also inhibited the combination of the ABCG1 and PLIN1. Geniposide alleviated AS by restoring PARP1/PI3K/AKT signaling pathway-suppressed lipophagy. This study is the first to present the lipophagy-inducing effect of Geniposide and the binding of ABCG1 and PLIN1 inhibited by PARP1.

中文翻译:


京尼平苷通过抑制 PARP1/PI3K/AKT 信号通路恢复脂肪吞噬来改善动脉粥样硬化



动脉粥样硬化(AS)是全球死亡的主要原因,表现为动脉脂质堆积和斑块形成。 Geniposide 是一种从 Gardenia jasminoides J.Ellis 中提取的环烯醚萜苷,可通过介导自噬来改善 AS。然而,京尼平苷如何调节自噬和治疗 AS 仍不清楚。评价京尼平苷治疗AS的疗效及机制。 , 京尼平苷可逆转高脂饮食引起的高脂血症、斑块进展和炎症。 , 京尼平苷通过抑制脂质堆积、细胞凋亡和泡沫细胞标志物的表达来抑制 VSMC 衍生的泡沫细胞形成。网络药理学分析和验证表明京尼平苷通过抑制 PI3K/AKT 信号通路增强脂肪自噬来治疗 AS。京尼平苷在缓解 AS 方面的益处被氯喹和 所抵消。使用 Olaparib 抑制 PARP1 可促进脂肪自噬并减轻 AS 进展,而 PARP1 过度表达则加剧泡沫细胞形成和脂肪自噬阻塞。 PARP1的上述作用被PI3K抑制剂LY294002减弱。 PARP1 还抑制 ABCG1 和 PLIN1 的结合。京尼平苷通过恢复 PARP1/PI3K/AKT 信号通路抑制的脂肪吞噬来缓解 AS。这项研究首次提出了京尼平苷的自脂诱导作用以及 PARP1 抑制 ABCG1 和 PLIN1 的结合。
更新日期:2024-04-10
down
wechat
bug